344 drugs passed the preliminary review of the medical insurance catalogue adjustment plan

Recently, the National Medical Insurance Bureau issued an announcement on the preliminary formal review of the adjustment of the medical insurance drug catalog, and a total of 344 drugs passed the preliminary review
.

According to the public information, the review does not set a time limit for the declaration of drugs for rare diseases "approved for listing after January 1, 2017", and at the same time, drugs included in the national list of encouraged generic drugs and encouraged research and development to declare children's drugs can be declared in this year's medical insurance directory
.

The industry believes that compared with the previous one, this adjustment has made appropriate inclination to special groups such as rare disease patients and children, which also means that more rare disease drugs will meet the declaration conditions
.

Data show that in the past 4 years, the national medical insurance drug catalog every year for dynamic adjustment, the current overall variety reached 2860, compared with the 2017 catalog increased by 325 kinds, through the negotiation of drug prices have been greatly reduced, 250 varieties of drugs average price reduction of 50%, so that many of the past sky-high prices, high-priced drugs become people-friendly drugs
.

Therefore, in the context of more rare disease drugs that meet the declaration conditions, it is expected that more high-priced drugs are also expected to enter medical insurance
.

This is mainly due to the fact that the protection of basic medical insurance for high-value rare disease drugs is more through
medical insurance negotiations at the national level.

Compared with the localities, the advantage of the "national talks" is that it is more likely to be "
exchanging quantity for price".

It is understood that in the adjustment of the national medical insurance catalogue in 2021, the "sky-high drug" noxinacin sodium injection for the treatment of rare disease spinal cord muscular atrophy, which is 700,000 yuan per injection, entered the new version of the medical insurance catalogue
with a "floor price" of less than 33,000 yuan per injection after medical insurance negotiations.

Such "soul bargaining" not only gives hope to rare disease patients, but also gives this group more attention
.

Up to now, more than 60 rare disease drugs have been approved for listing in China, of which more than 40 have entered the national medical insurance directory, involving 25 diseases
.

It is worth mentioning that in order to encourage domestic pharmaceutical companies to increase the research and development and production of rare disease drugs, the state has continued to introduce policies in recent years to encourage the research and development and production
of rare disease drugs.

For example, in 2022, CDE has issued two clinical guidelines for the clinical development of rare disease drugs, namely "Technical Guidelines for the Clinical Research and Development of Rare Disease Drugs" and "Guidelines for the Statistics of Clinical Research of Rare Disease Drugs (Trial)", which provides new ideas for the formulation of clinical trial protocols for rare disease drugs and also forms an important boost
from the technical aspect.

In general, the country's attention to the field of rare disease treatment is getting higher and higher, and it is constantly introducing favorable policies to support it, which is a heavy positive for the environment, and it will be good news
for rare disease treatment pharmaceutical companies and patients.

The industry said that with the development of the economy, the field of rare disease treatment has received increasing attention, and related enterprises are also expected to usher in a good opportunity for
development.

Some institutions predict that by 2025, the market size of rare disease drugs in China will reach 43.
8 billion yuan.


At the same time, with the continuous emergence of rare disease drugs and the entry into health insurance, patients will also have more medication options
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.